Table 1 Clinical characteristics and prognostic factors.
From: Selective elimination of immunosuppressive T cells in patients with multiple myeloma
Characteristics | A (Without Elotuzumab) | B (Elotuzumab) | All | ||||
|---|---|---|---|---|---|---|---|
Age | Median (range) | 59 (41–70); 1 missing | 59 (33–70) | 59 (33–70); 1 | |||
n | (%) | n | (%) | n | (%) | ||
Sex p = 0.81 | Female | 66 | 47.5 | 57 | 45.2 | 123 | 46.4 |
Male | 73 | 52.5 | 69 | 54.8 | 142 | 53.6 | |
Heavy chain type p = 0.66 | IgA | 23 | 16.6 | 22 | 17.5 | 45 | 17.0 |
IgG | 90 | 64.8 | 79 | 62.7 | 169 | 63.8 | |
Other (IgM, IgD, IgE) | 0 | 0.0 | 2 | 1.6 | 2 | 0.8 | |
None | 26 | 18.7 | 23 | 18.2 | 49 | 18.5 | |
Light chain type p = 0.70 | Kappa | 91 | 65.5 | 79 | 62.7 | 170 | 64.2 |
Lambda | 48 | 34.5 | 47 | 37.3 | 95 | 35.9 | |
ISSa p = 0.52 | I | 56 | 40.3 | 59 | 46.8 | 115 | 43.4 |
II | 49 | 35.2 | 42 | 33.3 | 91 | 34.3 | |
III | 34 | 24.5 | 25 | 19.8 | 59 | 22.3 | |
Cytogenetic risk groupb p = 0.88 | 0 | 73 | 65.2 | 67 | 67.0 | 140 | 66.0 |
1 | 39 | 34.8 | 33 | 33.0 | 72 | 34.0 | |
missing | 27 | 26 | 53 | ||||
